Brokerages Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $7.60

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received an average recommendation of "Buy" from the five brokerages that are covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $7.60.

A number of research firms recently issued reports on PRQR. Raymond James raised ProQR Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the company from $6.00 to $14.00 in a research report on Tuesday, October 29th. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, November 28th. Finally, JMP Securities restated a "market outperform" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th.

ProQR Therapeutics Stock Performance

Shares of PRQR stock traded down $0.14 during trading on Monday, hitting $2.62. 226,802 shares of the company were exchanged, compared to its average volume of 207,534. The firm has a market capitalization of $214.00 million, a price-to-earnings ratio of -8.19 and a beta of 0.30. The business's 50-day simple moving average is $3.31 and its 200 day simple moving average is $2.49. ProQR Therapeutics has a twelve month low of $1.61 and a twelve month high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Privium Fund Management B.V. raised its holdings in ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company's stock worth $10,251,000 after acquiring an additional 51,663 shares during the period. BNP Paribas Financial Markets lifted its position in shares of ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 7,300 shares during the last quarter. Finally, OneDigital Investment Advisors LLC boosted its stake in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 15,550 shares during the period. Institutional investors and hedge funds own 32.65% of the company's stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).